Stocks / NASDAQ / Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals, Inc.

Our Opinion

Marinus Pharmaceuticals, Inc. is on the Cruelty Free Investing list for exploiting animals because the company does animal testing for some of their medical products and clinical research.

Supporting Evidence:

The company stated in the following press release that they conduct pre-clinical trials of their drugs on animals.

“The data in the poster demonstrated that sub-therapeutic doses of diazepam and ganaxolone when administered in combination 15 minutes after onset of status epilepticus produced a partial or complete block of treatment-resistant status epilepticus in a rat model of SE, a clinically translatable model of this condition.” Read the following article

Company Description

Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of neuropsychiatric therapeutics. Its clinical stage drug candidate, ganaxolone, is a novel synthetic small molecule that is an analog of allopregnanolone, a natural occurring neurosteriod produced by the human body, which modulates gamma-aminobutyric acid a neurotransmitter in the brain. The company was founded by Geoffrey E. Chaiken, Harry H. Penner Jr., Vincent A. Pieribone and Kenneth R. Shaw on August 14, 2003 and is headquartered in Radnor, PA. [Source: MarketWatch]

Company Website: